CALR and neoplasm: In addition to autophagic cell death, it has been shown that combining oncolytic Ad with temozolomide not only decreases tumor growth but evokes immunogenic cell death via upregulation of high mobility group box protein 1 (HMGB1), CRT, and ATP, which collectively stimulate various anti-tumor immune responses [190].